According to Aotai Biological announcement, the net profit in 2021 is expected to be 705 million yuan to 795 million yuan, an increase of 3.78% Mel 17.05% over the same period last year. COVID-19 's testing business has maintained steady growth.
The chairman of the company is Gao Fei. Mr. Gao Fei: born in February 1974, Chinese nationality, master's degree, joined Aikang Biotechnology (Hangzhou) Co., Ltd. in June 1998. He has served as head of research and development, research and development manager, director of research and development, deputy general manager of research and development; general manager of Aibo Biopharmaceutical (Hangzhou) Co., Ltd., from December 2005 to April 2011. Executive Deputy General Manager of Hangzhou Biopharmaceutical National High-Tech Industrial Base Investment Management Co., Ltd., from June 2011 to June 2014; General Manager of Hangzhou Aotai Biotechnology Co., Ltd., from July 2014 to November 2017, and chairman and general manager of the company since November 2017.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If you have any questions, please contact us.